Wolfgang Miesbach: First Lp(a)‑Specific Therapy in Secondary Prevention?
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn about a recent article by Klaus G Parhofer et al, published in European Heart Journal, adding:
”First Lp(a)‑Specific Therapy in Secondary Prevention?
Pelacarsen Slashes Apheresis in Established CVD.
Elevated lipoprotein(a) [Lp(a)] is a frequent, genetically driven and largely lifestyle‑independent risk factor, present in approximately 20% of the general population and up to 25% of patients with ASCVD – yet we still have no approved Lp(a)‑lowering drug.
In the German Phase 3 Lp(a)FRONTIERS APHERESIS trial (51 patients with established CVD, isolated Lp(a) >60 mg/dL and a median of 44 LA sessions/year), pelacarsen 80 mg SC every 4 weeks almost abolished the need for weekly Lp(a) apheresis:
- normalized LA rate from 0.93 to 0.16 (≈99% reduction in odds of requiring LA),
- 69% complete LA avoidance from week 12–52 vs 0% on placebo,
- and ~72–77% sustained Lp(a) lowering, with mainly mild injection‑site reactions.
Huge congratulations to Dr Klaus Parhofer, Elisabeth Steinhagen-Thiessen and all co‑authors on these impressive data.
Pelacarsen may represent a major step toward a targeted, scalable therapy for genetically elevated Lp(a) in secondary prevention.”
Title: Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial
Authors: Klaus G. Parhofer, Ulrich Julius, Anna Laura Herzog, Thilo Krüger, Julia Weinmann-Menke, Gunnar H. Heine, Hui Cao, Jessica Schorr, Philippe Ferber, Jing Wang, Enrico Cristante, Björn Müller-Edenborn, Anja Vogt, Volker Schettler, Elisabeth Steinhagen-Thiessen

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 13, 2026, 03:21Abdul Muqtadir Abbasi: Iron Deficiency Beyond Anemia and the Importance of Finding the Cause
-
Nov 13, 2026, 03:05Marc Carrier: Aspirin vs Anticoagulants for VTE Prevention After Joint Replacement
-
Nov 13, 2026, 02:28Julia Sjöberg: ROCK1 Inhibition and Red Blood Cell Recovery After Chemotherapy
-
Nov 13, 2026, 02:07Tonie Reincke: Understanding Deep Vein Thrombosis and Vascular Health
-
Nov 13, 2026, 01:52Akshita Singh: The Remarkable Process of Blood Clotting
-
Nov 12, 2026, 22:52Milka Koupenova: The Role of Platelet RIG-I in Regulating Thrombotic Responses
-
Nov 12, 2026, 22:50Arun V J: Why Has India Still Not Achieved 100% Voluntary Blood Donation?
-
Nov 12, 2026, 22:49Sickle Cell Disease Deserves to Be Prioritised in Ghana – ISCC
-
Nov 12, 2026, 22:47Samir Kumar Beura: Delighted to Serve as a Topic Editor for a Research Topic in Frontiers in Neuroscience